Are you Struggling With Losing Weight?
The purpose of this study is to find out whether an experimental medication helps people living with obesity, who may also have diabetes, to lose weight.
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of experimental medication ALN-KHK to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
Would you like to take part?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with obesity and weight loss, and whether it will be made widely available to all Canadians trying to manage obesity. Study volunteers are an important part of moving medical care forward.
You may qualify to participate in this study if you:
- Have a stable euthyroid status (no known changes in thyroid function; stable hormone replacement for at least 4 months) at screening
- Are between the ages of 18 and 65 years, inclusive
- For Part A: have a body mass index (BMI) ≥27 kg/m^2 and ≤34.9 kg/m^2
- For Part B: have a BMI ≥30 kg/m^2 to ≤39.9 kg/m^2, confirmed diagnosis of T2DM, and an HbA1c ≥7.5% to <10%
- For Part B: have a confirmed T2DM diagnosis (≤8 years)
You may not qualify to participate if you:
- For Parts A and B: have received an investigational medication within the last 30 days
- For Part A: have a history of Type 1 or Type 2 diabetes
- For Part B: have a history of Type 1 diabetes
There are other eligibility requirements that the study doctor will review. Only the study doctor can finally determine whether you are eligible to participate in the study or not.